AKT and PAX3-FKHR Cooperation Enforces Myogenic Differentiation Blockade in Alveolar Rhabdomyosarcoma Cell

Overview

Journal Cell Cycle

Specialty Cell Biology

Date 2012 Feb 16

PMID 22333587

Citations 12

Authors

Mathivanan Jothi

Kochi Nishijo

Charles Keller

Asoke K Mal

Affiliations

Soon will be listed here.

Abstract

The chimeric PAX3-FKHR transcription factor is present in a majority of alveolar rhabdomyosarcoma (ARMS), an aggressive skeletal muscle cancer of childhood. PAX3-FKHR-mediated aberrant myogenic gene expression resulting in escape from terminal differentiation program is believed to contribute in ARMS development. In skeletal muscle differentiation, activation of AKT pathway leads to myogenic gene activation and terminal differentiation. Here, we report that AKT acts, in part, by modulating PAX3-FKHR transcriptional activity via phosphorylation in the maintenance of the myogenic differentiation blockade in established mouse models of ARMS cells. We observed that low levels of AKT activity are associated with elevated levels of PAX3-FKHR transcriptional activity, and AKT hyperactivation results in PAX3-FKHR phosphorylation coupled with decreased activity once cells are under differentiation-permissible conditions. Subsequent data shows that attenuated AKT activity-associated PAX3-FKHR activity is required to suppress the function of MyoD, a key myogenic regulator of muscle differentiation. Conversely, decreased PAX3-FKHR activity results in the eradication of MyoD expression and subsequent suppression of the myogenic differentiation. Thus, AKT regulation of the PAX3- FKHR suppresses myogenic gene expression in ARMS cells, causing a failure in differentiation. Evidence is presented that provides a novel molecular link between AKT and PAX3-FKHR in maintaining myogenic differentiation blockade in ARMS.

Citing Articles

FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma.

Milewski D, Shukla S, Gryder B, Pradhan A, Donovan J, Sudha P Oncogene. 2021; 40(12):2182-2199.

PMID: 33627785 PMC: 8005492. DOI: 10.1038/s41388-021-01694-9.

Targeting the undruggable: exploiting neomorphic features of fusion oncoproteins in childhood sarcomas for innovative therapies.

Knott M, Holting T, Ohmura S, Kirchner T, Cidre-Aranaz F, Grunewald T Cancer Metastasis Rev. 2020; 38(4):625-642.

PMID: 31970591 PMC: 6994515. DOI: 10.1007/s10555-019-09839-9.

NRF2 orchestrates the redox regulation induced by radiation therapy, sustaining embryonal and alveolar rhabdomyosarcoma cells radioresistance.

Marampon F, Codenotti S, Megiorni F, Del Fattore A, Camero S, Gravina G J Cancer Res Clin Oncol. 2019; 145(4):881-893.

PMID: 30701326 DOI: 10.1007/s00432-019-02851-0.

Camptothecin exhibits topoisomerase1-independent KMT1A suppression and myogenic differentiation in alveolar rhabdomyosarcoma cells.

Wolff D, Lee M, Jothi M, Mal M, Li F, Mal A Oncotarget. 2018; 9(40):25796-25807.

PMID: 29899822 PMC: 5995248. DOI: 10.18632/oncotarget.25376.

regulated by PAX3/FOXO1 fusion contributes to the acquisition of aggressive behavior in PAX3/FOXO1-positive alveolar rhabdomyosarcoma.

Akaike K, Suehara Y, Kohsaka S, Hayashi T, Tanabe Y, Kazuno S Oncotarget. 2018; 9(38):25206-25215.

PMID: 29861864 PMC: 5982774. DOI: 10.18632/oncotarget.25392.

References

Nishijo K, Chen Q, Zhang L, McCleish A, Rodriguez A, Cho M . Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma. Cancer Res. 2009; 69(7):2902-11. PMC: 2789740. DOI: 10.1158/0008-5472.CAN-08-3723. View

Linardic C . PAX3-FOXO1 fusion gene in rhabdomyosarcoma. Cancer Lett. 2008; 270(1):10-8. PMC: 2575376. DOI: 10.1016/j.canlet.2008.03.035. View

Zhang Y, Schwartz J, Wang C . Comparative analysis of paired- and homeodomain-specific roles in PAX3-FKHR oncogenesis. Int J Clin Exp Pathol. 2009; 2(4):370-83. PMC: 2615594. View

Chalepakis G, Fritsch R, Fickenscher H, Deutsch U, Goulding M, Gruss P . The molecular basis of the undulated/Pax-1 mutation. Cell. 1991; 66(5):873-84. DOI: 10.1016/0092-8674(91)90434-z. View

Mercado G, Barr F . Fusions involving PAX and FOX genes in the molecular pathogenesis of alveolar rhabdomyosarcoma: recent advances. Curr Mol Med. 2007; 7(1):47-61. DOI: 10.2174/156652407779940440. View

Cao Y, Kumar R, Penn B, Berkes C, Kooperberg C, Boyer L . Global and gene-specific analyses show distinct roles for Myod and Myog at a common set of promoters. EMBO J. 2006; 25(3):502-11. PMC: 1383539. DOI: 10.1038/sj.emboj.7600958. View

Bennicelli J, EDWARDS R, Barr F . Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma. Proc Natl Acad Sci U S A. 1996; 93(11):5455-9. PMC: 39267. DOI: 10.1073/pnas.93.11.5455. View

Cao L, Yu Y, Bilke S, Walker R, Mayeenuddin L, Azorsa D . Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res. 2010; 70(16):6497-508. PMC: 2922412. DOI: 10.1158/0008-5472.CAN-10-0582. View

Ridgeway A, Skerjanc I . Pax3 is essential for skeletal myogenesis and the expression of Six1 and Eya2. J Biol Chem. 2001; 276(22):19033-9. DOI: 10.1074/jbc.M011491200. View

10.

Dietz K, Miller P, Iyengar A, Loupe J, Hollenbach A . Identification of serines 201 and 209 as sites of Pax3 phosphorylation and the altered phosphorylation status of Pax3-FOXO1 during early myogenic differentiation. Int J Biochem Cell Biol. 2011; 43(6):936-45. PMC: 3095663. DOI: 10.1016/j.biocel.2011.03.010. View

11.

Rotwein P, Wilson E . Distinct actions of Akt1 and Akt2 in skeletal muscle differentiation. J Cell Physiol. 2009; 219(2):503-11. PMC: 2750805. DOI: 10.1002/jcp.21692. View

12.

Zhang L, Wang C . Identification of a new class of PAX3-FKHR target promoters: a role of the Pax3 paired box DNA binding domain. Oncogene. 2006; 26(11):1595-605. PMC: 2238811. DOI: 10.1038/sj.onc.1209958. View

13.

Li Y, Jiang B, Ensign W, Vogt P, Han J . Myogenic differentiation requires signalling through both phosphatidylinositol 3-kinase and p38 MAP kinase. Cell Signal. 2001; 12(11-12):751-7. DOI: 10.1016/s0898-6568(00)00120-0. View

14.

Barr F . Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene. 2001; 20(40):5736-46. DOI: 10.1038/sj.onc.1204599. View

15.

Xia S, Pressey J, Barr F . Molecular pathogenesis of rhabdomyosarcoma. Cancer Biol Ther. 2002; 1(2):97-104. DOI: 10.4161/cbt.51. View

16.

Relaix F, Polimeni M, Rocancourt D, Ponzetto C, Schafer B, Buckingham M . The transcriptional activator PAX3-FKHR rescues the defects of Pax3 mutant mice but induces a myogenic gain-of-function phenotype with ligand-independent activation of Met signaling in vivo. Genes Dev. 2003; 17(23):2950-65. PMC: 289153. DOI: 10.1101/gad.281203. View

17.

Accili D, Arden K . FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell. 2004; 117(4):421-6. DOI: 10.1016/s0092-8674(04)00452-0. View

18.

Kikuchi K, Tsuchiya K, Otabe O, Gotoh T, Tamura S, Katsumi Y . Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma. Biochem Biophys Res Commun. 2007; 365(3):568-74. DOI: 10.1016/j.bbrc.2007.11.017. View

19.

Tureckova J, Wilson E, Cappalonga J, Rotwein P . Insulin-like growth factor-mediated muscle differentiation: collaboration between phosphatidylinositol 3-kinase-Akt-signaling pathways and myogenin. J Biol Chem. 2001; 276(42):39264-70. DOI: 10.1074/jbc.M104991200. View

20.

Linardic C, Naini S, Herndon 2nd J, Kesserwan C, Qualman S, Counter C . The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence. Cancer Res. 2007; 67(14):6691-9. DOI: 10.1158/0008-5472.CAN-06-3210. View